Notice of General Meeting and Publication of Circular
05 April 2023 - 4:00PM
OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO)
("
OKYO" or the "
Company"), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease to address the
significant unmet need in this multi-billion-dollar market,
announces that, further to its announcement on 4 April 2023, it has
today posted a circular (the "
Circular") to
shareholders which contains further details regarding the proposed
cancellation of its ordinary shares of no par value each
("
Ordinary Shares") from listing on the standard
segment of the Official List of the Financial Conduct Authority and
trading on the main market for listed securities of London Stock
Exchange plc and associated timetable, together with proposals to
be put to shareholders at a general meeting of the Company to be
held at the offices of Orrick, Herrington & Sutcliffe (UK) LLP
at 107 Cheapside, London EC2V 6DN, United Kingdom at 12.00 midday
on 3 May 2023 (the "
General Meeting"), including,
inter alia, to consolidate every 65 existing Ordinary Shares into
one new ordinary share of no par value (thereby matching its
current American Depositary Share ratio). The Circular will shortly
be posted to the Company’s website at:
https://okyopharma.com/investors/corporate-governance/corporate-documents/
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
+44 (0)20 7495 2379 |
Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
|
|
|
Broker |
Robert Emmet, Optiva Securities Limited |
+44 (0)20 3981 4173 |
Notes for Editors:
About OKYOOKYO Pharma Limited
(LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to
listing on NASDAQ and on the standard segment of the Official List
of the UK Financial Conduct Authority and to trading on the main
market for listed securities of London Stock Exchange plc. OKYO is
focusing on the discovery and development of novel molecules to
treat inflammatory dry eye diseases and chronic pain. For further
information, please visit www.okyopharma.com.
About OK-101OK-101 is a lipid
conjugated chemerin peptide antagonist of the ChemR23 G-protein
coupled receptor which is typically found on immune cells of the
eye responsible for the inflammatory response. OK-101 was developed
using a membrane-anchored-peptide (MAP) technology to produce a
novel long-acting drug candidate for treating dry eye disease.
OK-101 has been shown to produce anti-inflammatory and
pain-reducing activities in mouse models of dry eye disease and
corneal neuropathic pain; and is designed to combat washout through
the inclusion of the lipid ‘anchor’ contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular
environment.
NOT FOR RELEASE, PUBLICATION OR
DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR
INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A
VIOLATION OF THE LAWS OF SUCH JURISDICTION. NEITHER THIS
ANNOUNCEMENT, NOR ANYTHING CONTAINED HEREIN, SHALL FORM THE BASIS
OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT
WHATSOEVER IN ANY JURISDICTION.
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024